Compare EKSO & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EKSO | PMN |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 34.6M |
| IPO Year | 2012 | 2022 |
| Metric | EKSO | PMN |
|---|---|---|
| Price | $10.11 | $24.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $9.50 | ★ $42.67 |
| AVG Volume (30 Days) | 154.8K | ★ 190.9K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.76 | ★ 110.28 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $81.23 | N/A |
| Revenue Next Year | $7.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.29 |
| 52 Week High | $13.27 | $21.83 |
| Indicator | EKSO | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 87.14 |
| Support Level | $8.71 | $0.43 |
| Resistance Level | $10.76 | N/A |
| Average True Range (ATR) | 1.05 | 1.71 |
| MACD | -0.19 | 0.64 |
| Stochastic Oscillator | 29.52 | 98.91 |
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.